Provided by Tiger Trade Technology Pte. Ltd.

Verrica Pharmaceuticals Inc.

5.49
+0.20003.78%
Volume:129.62K
Turnover:714.05K
Market Cap:94.31M
PE:-3.27
High:5.60
Open:5.31
Low:4.99
Close:5.29
52wk High:9.82
52wk Low:3.28
Shares:17.18M
Float Shares:6.78M
Volume Ratio:1.79
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6800
EPS(LYR):-14.7812
ROE:-240.35%
ROA:-14.74%
PB:3.81
PE(LYR):-0.37

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR)

TIPRANKS
·
Mar 12

Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand

Reuters
·
Mar 11

Verrica FY 2025 total revenue rose 370% to USD 35.58 million as net loss narrowed 77% to USD 17.89 million

Reuters
·
Mar 11

Verrica Pharmaceuticals Q4 Adj. EPS $(0.51) Beats $(0.79) Estimate, Sales $5.092M Beat $4.525M Estimate

Benzinga
·
Mar 11

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals: Co Advancing Vp-315 Toward Phase 3 Program for Basal Cell Carcinoma in 2026

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals: Co Expects to Initiate Second Phase 3 Study of Ycanth in US, Japan With Torii Pharmaceutical in Mid-2026

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals Q4 Adjusted Net Income USD -7.2 Million

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals Q4 Net Income USD -8.074 Million

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals Q4 Income From Operations USD -7.192 Million

THOMSON REUTERS
·
Mar 11

Verrica Pharmaceuticals Inc expected to post a loss of 79 cents a share - Earnings Preview

Reuters
·
Mar 07

Verrica Pharmaceuticals Inc. to Report Q4 and Full-Year Financial Results and Provide Corporate Update

Reuters
·
Mar 05

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

THOMSON REUTERS
·
Mar 05

Verrica Pharmaceuticals Names Chris Chapman Chief Commercial Officer

Reuters
·
Feb 12

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

THOMSON REUTERS
·
Feb 12

Verrica Pharmaceuticals Launches YCANTH in Japan with Torii Pharmaceutical

Reuters
·
Feb 09

Verrica Pharmaceuticals Announces Launch of Ycanth® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

THOMSON REUTERS
·
Feb 09

Verrica Pharmaceuticals Files Initial Beneficial Ownership Statement for BKB Growth Investments

Reuters
·
Jan 27

BRIEF-Verrica Pharmaceuticals Announces First Patient Dosed In Phase 3 Program

Reuters
·
Jan 07

Verrica Pharmaceuticals Doses First Patient in Phase 3 Trial of YCANTH for Common Warts

Reuters
·
Jan 07